top of page

News

January 2, 2024


Azome Therapeutics, an early-stage drug discovery company, announced today that the company has been selected to present at the upcoming Biotech Showcase 2024, a premier investor conference, from January 8-10, 2024 in San Francisco, CA.  


More than 3,500 international investors and companies are expected to attend this year’s Biotech Showcase. Azome Therapeutics is one of approximately 350 companies that have been selected to present during the 2-day event.


The Azome presentation will highlight positive preclinical research supporting the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform, which blocks inflammasome activation, and its lead drug candidate, AZM-152.


“We are very excited to be one of the select companies invited to present at this year’s showcase,” said Azome Therapeutics CEO Elliott Gruskin, PhD.  “Based on the latest research we will be presenting, our RHAMM antagonist platform is demonstrating excellent potential for advancing the treatment of severe inflammatory diseases, including several that have significant unmet needs.”


Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, acute respiratory distress syndrome, bronchopulmonary dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks key upstream priming and activation signals involved in the aberrant activation of the NLRP3 inflammatory cascade.

December 19, 2023


Rashmin C. Savani, MBChB, Head of Scientific Advisory Board, Azome Therapeutics, spoke on the critical role of RHAMM ((Receptor for Hyaluronan-Mediated Motility) in inflammasome activation at the 15th Annual Bowman Symposium on Neonatal Research held on November 8-9 at The Children’s Hospital Research Institute of Manitoba in Winnipeg, Canada.


Dr. Savani’s talk, ““The Pathophysiology of Lung Injury and Inflammation,” discussed the mechanisms controlling inflammation and the role of inflammasome activation in disease processes. During the symposium, he also participated in a Cardiorespiratory Research “Meet the Experts” panel hosted by the Biology of Breathing Research Trainees’ Hub.


Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, Acute Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.

November 20, 2023


Azome Therapeutics’ groundbreaking peptide technology that blocks inflammasome activation was the subject of a talk given by Rashmin C. Savani, MBChB, Head of Scientific Advisory Board at the Biennial Meeting of the American Society for Matrix Biology held in Salt Lake City, October 22–25.


In his presentation, “Towards the Universality of TLR Signaling: Developing Novel Therapeutics,” Dr. Savani provided an overview of the research supporting the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform.


Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, Acute Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia. The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.


bottom of page